South Korea: In a post hoc analysis of the randomized PULSAR trial, aflibercept 8 mg demonstrated noninferior visual outcomes ...
Oral micronutrient supplementation showed no benefit on geographic atrophy lesion growth among a patient group from the OAKS and DERBY trials, according to a speaker ...
Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...
New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...
MedPage Today on MSN
Prediabetes Reversal Benefits; Many Seniors Quit GLP-1s in a Year; Testosterone Fads
Starting an incretin receptor agonist -- especially tirzepatide (Mounjaro, Zepbound) -- was associated with reduced risks of ...
The prospective data indicate that clinicians should be aggressive with lipid-lowering therapies in these patients, experts say.
Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, outperforming placebo. The FDA approval of oral semaglutide marks the first GLP-1 pill for chronic weight management, ...
Traditional rule-based systems, once sufficient for detecting simple patterns of fraud, have been overwhelmed by the scale, ...
Nemolizumab rapidly relieves itch and sleep disturbance among patients with moderate-to-severe atopic dermatitis (AD) and ...
On December 24, President Ilham Aliyev and First Lady Mehriban Aliyeva visited several liberated areas, a visit that carried ...
A new study supports strict adherence to guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets following ...
ZME Science on MSN
Obesity Patients Lost Nearly 30 percent of Their Body Weight on a New Experimental Drug and Many Saw Their Knee Pain Disappear
In a new clinical trial, people with obesity and knee osteoarthritis who took an experimental drug from Eli Lilly lost large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback